Hemagglutinin and other influenza viral antigens (HA/NA/M2)

Hemagglutinin (HA) and other influenza viral antigens, such as Neuraminidase (NA) and Matrix protein 2 (M2), are the primary molecular targets for influenza prevention and treatment (NIH, 2023). HA is a surface glycoprotein that mediates viral attachment to host sialic acid receptors and subsequent membrane fusion, serving as the key component in seasonal vaccines to elicit neutralizing antibodies (Wikipedia, 2024). NA is an enzyme that facilitates the release of new viral particles by cleaving sialic acid, and it is the target of inhibitors like oseltamivir (PubChem, 2024). The M2 protein functions as a proton channel necessary for viral uncoating, though its use as a drug target is limited by widespread resistance to adamantanes (StatPearls, 2023). Additionally, the viral polymerase complex (PA, PB1, PB2) has emerged as a target for newer antivirals like baloxavir marboxil, which inhibits the cap-dependent endonuclease activity (PubMed, 2021). These antigens are subject to constant evolution through antigenic drift and shift, necessitating regular updates to therapeutic and prophylactic strategies. Targeting these proteins is essential for managing both seasonal epidemics and potential pandemic outbreaks.

Other names

Influenza virus surface proteinsInfluenza antigensHemagglutininNeuraminidaseMatrix protein 2NucleoproteinPolymerase acidic protein

Drugs targeting these antigens work through several distinct pathways: Hemagglutinin inhibitors (e.g., umifenovir) prevent viral-host membrane fusion; Neuraminidase inhibitors (e.g., oseltamivir) block the enzymatic cleavage of sialic acid to prevent viral shedding; M2 ion channel blockers (e.g., amantadine) inhibit the acidification of the viral interior required for uncoating; and polymerase inhibitors (e.g., baloxavir) disrupt viral mRNA synthesis (NIH, 2023; StatPearls, 2023).